Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi FamiliesSeeking Alpha • 01/23/24
Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024Business Wire • 12/21/23
Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)Business Wire • 12/14/23
Acadia Soars To A Four-Month High After Winning A Patent Battle For Its Biggest DrugInvestors Business Daily • 12/13/23
Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent LitigationBusiness Wire • 12/13/23
Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi SyndromeBusiness Wire • 11/30/23
Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study (Revised)Zacks Investment Research • 11/30/23
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer's Disease PsychosisBusiness Wire • 11/27/23
5 Biotech Stocks Likely to Thrive as Industry Prospects Look BrightZacks Investment Research • 11/22/23
Acadia Pharmaceuticals Announces Change in Research and Development LeadershipBusiness Wire • 11/21/23
Wall Street Analysts Predict a 37.65% Upside in Acadia (ACAD): Here's What You Should KnowZacks Investment Research • 11/20/23
Are Medical Stocks Lagging ACADIA Pharmaceuticals (ACAD) This Year?Zacks Investment Research • 11/17/23
Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating OverviewBusiness Wire • 11/02/23
Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology ConferenceBusiness Wire • 10/31/23